Form 8-K OMEROS CORP For: Oct 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Maxim Group Comments on Omeros (OMER) Following New Omidria Supply Agreement
October 7, 2014 2:11 PM EDTMaxim Group affirms Omeros (Nasdaq: OMER) at Buy with a price target of $24 following news that the company and Hospira Worldwide entered into a Commercial Supply Agreement, pursuant to which Hospira will act as a non-exclusive supplier of Omeros product Omidria for commercial sale in the United States and the European Union.
Analyst Jason Kolbert commented:
Omidria has been approved and we currently assume OMS302 (intraocular lens replacement surgery) we will see a full launch in 4Q2014, with some modest sales having occurred in 3Q2014. Our valuation parameters still point... MoreOmeros Corp. (OMER), Hospira (HSP) Enter Supply Agreement for Omidria
October 7, 2014 7:03 AM EDTOn October 3, 2014, Omeros Corporation (Nasdaq: OMER), Hospira S.p.A., and Hospira Worldwide, Inc. (NYSE: HSP) entered into a Commercial Supply Agreement (the Supply Agreement), pursuant to which Hospira will act as a non-exclusive supplier of Omeros product Omidria for commercial sale in the United States and the European Union (the Territory).
Pursuant to the Supply Agreement, Hospira has agreed to manufacture and supply, and Omeros has agreed to purchase, a minimum percentage of Omeros requirements of Omidria for commercial sales and clinical supplies for the development of additional... More
